SQZ, Roche expand deal to jointly develop cancer cell therapies

By Mark Zipkin | Oct 15, 2018 | 2:41 PM GMT

SQZ Biotechnologies Co. (Watertown, Mass.) and Roche (SIX:ROG; OTCQX:RHHBY) expanded a 2015 deal to co-develop and commercialize antigen presenting cell (APC) therapies to treat cancers that are difficult to address with other adoptive cell therapy strategies.

The

Read the full 378 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE